Department of Radiology, Addenbrooke's Hospital, University of Cambridge, Hills Road, Cambridge CB2 1QQ, UK.
Nat Rev Urol. 2012 Jan 17;9(2):94-101. doi: 10.1038/nrurol.2011.222.
A significant amount of research has focused on the role of diffusion-weighted MRI (DW-MRI) in the management of patients with prostate cancer. Although uncertainties remain, a clearer picture of where this technique fits into clinical practice is now available. A combination of DW-MRI and T2-weighted MRI (T2W-MRI) demonstrates improved accuracy for lesion detection and localization compared with T2W-MRI alone, and has been suggested as a tool to guide tissue biopsy. DW-MRI could also have roles in active surveillance, evaluating treatment efficacy, and predicting disease recurrence. Furthermore, DW-MRI offers the exciting possibility of gathering information about tumor characteristics and aggressiveness in a noninvasive manner. Validation in large prospective multicenter trials is critical if this technique is to be integrated into current management algorithms for prostate cancer.
大量研究集中在扩散加权磁共振成像（DW-MRI）在前列腺癌患者管理中的作用。尽管仍存在不确定性，但现在可以更清楚地了解该技术在临床实践中的应用。DW-MRI 与 T2 加权磁共振成像（T2W-MRI）相结合，在检测和定位病变方面比单独使用 T2W-MRI 具有更高的准确性，并且已被建议作为指导组织活检的工具。DW-MRI 还可以在主动监测、评估治疗效果和预测疾病复发中发挥作用。此外，DW-MRI 提供了一种以非侵入性方式获取肿瘤特征和侵袭性信息的令人兴奋的可能性。如果要将该技术整合到前列腺癌的当前管理算法中，那么在大型前瞻性多中心试验中进行验证至关重要。
